Related Experiment Videos
Pediatric acute blastic natural killer cell leukemia.
Steven G DuBois1, Joan E Etzell, Katherine K Matthay
1Department of Pediatrics, School of Medicine, University of California, San Francisco 94143-0106, USA.
Leukemia & Lymphoma
|August 3, 2002
Summary
This report details a rare pediatric blastic natural killer (NK) cell leukemia case. Pediatric blastic NK cell leukemia is a distinct entity with a poor prognosis, differing from other pediatric NK cell leukemias.
Area of Science:
- Hematology
- Pediatric Oncology
- Immunology
Background:
- Natural Killer (NK) cell leukemia is a rare lymphoid malignancy.
- Pediatric NK cell leukemia is exceptionally uncommon, with limited data on its subtypes.
Observation:
- A 9-year-old girl presented with blastic NK cell leukemia, exhibiting an agranular phenotype (CD7+, CD45+, CD56+, HLA-DR+).
- The patient achieved initial remission with acute lymphoblastic leukemia (ALL)-directed chemotherapy but experienced multiple relapses.
- Literature review identified 9 additional pediatric cases, categorized into blastic, acute/aggressive, and myeloid precursor NK cell leukemia.
Findings:
- Pediatric blastic NK cell leukemia shows greater variability in age and race compared to acute/aggressive forms.
- Morphologic and immunophenotypic characteristics, including CD13/33 expression, differentiate subtypes.
- All pediatric NK cell leukemia subtypes demonstrated a poor prognosis.
Implications:
- Pediatric blastic NK cell leukemia represents a distinct clinicopathologic entity.
- Further research is needed to understand the unique biology and optimize treatment strategies for this rare malignancy.
- Improved diagnostic criteria and targeted therapies may enhance outcomes for affected children.